Carta Launches CRM with Acquisition of ListAlpha
3.3.2026 16:01:00 EET | Business Wire | Press release
Carta, the world’s first fully interconnected system for private capital, today announced it has acquired ListAlpha, the AI-powered CRM and relationship intelligence platform. The acquisition marks the launch of Carta CRM, a major expansion of the Carta ERP that further unifies front-to-back office workflows for the private markets.
Private equity and venture capital firms have long operated in a fragmented way, keeping relationship context in siloed CRMs while fund performance data remains trapped in back-office ledgers. This information silo quietly erodes clarity for deal teams and GPs, slowing down teams and decreasing capital velocity.
By integrating ListAlpha’s specialized CRM directly into the Carta ecosystem, firms can unify front-office intelligence with back-office execution on a single platform. Effectively, Carta now provides the industry’s first comprehensive ERP for private capital, managing the entire investment lifecycle—seamlessly linking workflows from initial investor outreach and deal sourcing through portfolio management and the final distribution of a successful exit.
“Last year, I wrote about our shift to build a vertical ERP for private markets—the NetSuite for our industry. While we had the core accounting and data stores, we were missing the front-office engine,” said Henry Ward, Chief Executive Officer, Carta. “As fund administration is to CFOs and finance teams, CRM is the foundational product for the GPs, deal teams, and IR teams. By bringing ListAlpha into the Carta ERP, we are removing the gap between relationship context and fund reality. Now, firms can own their entire fund lifecycle, from idea to investment to distribution, in one place.”
One Platform, Two Fronts: Bridging the Deal Team and IR
Unlike traditional, high-friction CRMs that often feel like a data-entry tax on deal teams, Carta’s networked CRM is a multi-use engine designed for the high-stakes, "many-to-many" relationships of private capital. It serves as the connective tissue between the deal team’s sourcing efforts and the IR team’s fundraising efforts:
- ForDeal Teams: CRM turns into a proactive sourcing tool. By automating interaction capture across Outlook and Google Workplace, deal teams leverage a networked CRM to identify proprietary leads, track targets through the funnel, and use AI to generate Investment Committee one-pagers in seconds.
- For Investor Relations: Investor Relations (IR) teams can now pitch with precision. By syncing live accounting data from the Carta Ledger directly to Limited Partner (LP) records, IR professionals can view real-time metrics like IRR, TVPI, and DPI alongside contact notes. This ensures they walk into every meeting with total confidence and the ability to match opportunities to LP appetite and liquidity.
The AI-Powered CRM: Unified Intelligence for Private Capital
Carta CRM gives mid-to-large cap firms access to a financial-grade system designed to modernize every interaction, including:
- Institutional-grade relationship intelligence and automated capture: Native integrations with Outlook, Gmail, and Calendar eliminate manual data entry. Every meeting, email, and sentiment is automatically logged, turning individual networks into a permanent firm-wide asset and preventing the "crossed wires" of uncoordinated outreach.
- Real-time fund performance synced directly to LP records: The live sync between the Carta Ledger and the CRM removes the "fragmented brain" of private capital. IR teams can instantly surface live metrics—including IRR, TVPI, DPI, and Carry—directly on LP records to provide data-backed answers in seconds.
- AI-powered deal evaluation and IC-ready outputs: Leveraging a specialized AI agent and MCP server architecture, deal teams can query years of history to identify proprietary leads and evaluate targets using qualitative judgment to render an “Investment Committee one-pager” in under 10 seconds.
- A single, flexible solution from sourcing to exit: The CRM provides customizable deal and fundraising pipelines within a financial-grade cloud environment. This ensures compliance with leading industry security standards while providing instant tracebacks from CRM notes to the underlying fund data.
“Joining Carta represents an exciting next chapter for the ListAlpha team,” said Ihar Valodzin, Founder and Chief Executive Officer, ListAlpha. “Most firms are frustrated by manual reconciliation between their CRM and existing data silos. By unifying firm-wide interactions with real-time economic data from Carta, we are giving investors the authority of a shared institutional memory — whether it's identifying proprietary leads or responding to LPs in minutes rather than days..”
Over the coming months, ListAlpha’s technology will be fully integrated into Carta’s platform. Existing ListAlpha clients will now be able to leverage the full power of the Carta ecosystem, including world-class fund administration, tax solutions, and compliance tools, which are already trusted by nearly 9,000 funds representing more than $203B in assets.
To learn more, visit https://carta.com/blog/listalpha-acquisition/. To learn more about Carta, follow us on LinkedIn, X, Instagram, Youtube, or visit carta.com
About Carta
Carta is the ERP for private capital, connecting the entire ecosystem—from GPs and LPs to CEOs, CFOs, employees, and advisors. Trusted by 50,000 companies in 160+ countries, our platform streamlines every ownership workflow, making it easier to understand, manage, and grow equity. With software and services built to scale, Carta empowers you to build, invest, and grow with confidence. Carta’s Fund Administration platform supports 9,000 funds and SPVs, representing $203B+ in assets under management, with tools designed to enhance the strategic impact of Fund CFOs. Recognized by Fortune, Forbes, Fast Company, Inc. and Great Places to Work, Carta is transforming how private capital operates.
For more information visit carta.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303307760/en/
Contacts
Media Contact:
Amanda Taggart, VP Communications
amanda.taggart@carta.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom